Curaleaf moves to halt Aurora share issuances
Rhea-AI Filing Summary
Curaleaf Holdings, Inc. (CURLF) disclosed that on September 14, 2026 it filed an application with the Alberta Securities Commission seeking to halt share issuances under Aurora’s at-the-market share issuance program while Curaleaf’s outstanding offer to acquire all of Aurora’s shares remains in effect. Curaleaf is pursuing an expedited hearing and states that Aurora’s ATM issuances have diluted Aurora shareholders and increased the overall cost of Curaleaf’s offer.
According to Curaleaf, Aurora has issued approximately 2.81 million shares at an average price of US$3.04 since Curaleaf first expressed transaction interest, increasing the value required to complete the offer by more than US$11 million, and contributing to shareholder dilution of about 4.9% over that period and 10.8% since the ATM program began in February 2026. The company reiterates that its tender offer is governed by an Offer to Purchase and Circular dated August 18, 2026 and related U.S. and Canadian securities filings.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Shares issued under ATM since Curaleaf interest: 2,810,000 shares
Average price of ATM issuances: US$3.04 per share
Increase in Curaleaf offer cost: More than US$11 million
+4 more
7 metrics
Shares issued under ATM since Curaleaf interest
2,810,000 shares
Aurora shares issued via ATM program since Curaleaf first expressed interest in a transaction
Average price of ATM issuances
US$3.04 per share
Average price of Aurora shares issued under ATM since Curaleaf’s initial approach
Increase in Curaleaf offer cost
More than US$11 million
Additional aggregate value Curaleaf states is required to complete its offer due to ATM issuances
Shareholder dilution since Curaleaf interest
4.9%
Aurora shareholder dilution attributed to ATM issuances since June 2026
Shareholder dilution since ATM implementation
10.8%
Aurora shareholder dilution attributed to ATM program since February 2026
Aurora cash balance cited
C$149 million
Approximate cash balance Aurora has described publicly, cited in Curaleaf’s application
Curaleaf offer reference price
US$4.00 per share
Offer price referenced by Curaleaf in discussing Aurora’s share issuances
Key Terms
at-the-market share issuance program, tender offer, Registration Statement on Form F-80, Schedule 14D-1F, +2 more
6 terms
tender offer regulatory
"The Offer is being conducted in accordance with Section 14(e) of the Exchange Act and Regulation 14E"
A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.
Registration Statement on Form F-80 regulatory
"Curaleaf has filed with the SEC a Registration Statement on Form F-80"
Schedule 14D-1F regulatory
"a Tender Offer Statement on Schedule 14D-1F under the U.S. Securities Exchange Act"
forward-looking information regulatory
"This document contains "forward-looking information" within the meaning of applicable Canadian securities laws"
Forward-looking information are predictions, plans, estimates or expectations about a company’s future performance, results or events, such as sales forecasts, project timelines, or anticipated costs. It matters to investors because these statements guide expectations but rely on assumptions and uncertain factors—like a weather forecast for a business—so investors should treat them as informed guesses rather than guarantees and consider the risks and possible changes behind the numbers.
Offer to Purchase and Circular financial
"The Offer by Curaleaf to purchase all outstanding Shares is made solely by the Offer to Purchase and Circular"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What action did Curaleaf Holdings (CURLF) announce regarding Aurora’s ATM program?
Curaleaf announced it filed an application with the Alberta Securities Commission seeking to halt share issuances under Aurora’s at-the-market share issuance program while Curaleaf’s offer to acquire all Aurora shares remains outstanding, and has requested an expedited hearing.
How does Curaleaf say Aurora’s ATM issuances affect the Curaleaf offer?
Curaleaf states that Aurora’s ATM share issuances have increased the aggregate value required to complete the offer by more than US$11 million and contributed to shareholder dilution, making it more difficult to reach offer acceptance thresholds.
What dilution levels does Curaleaf attribute to Aurora’s ATM program?
Curaleaf reports that the ATM program has diluted Aurora shareholders by approximately 10.8% since its implementation in February 2026 and by about 4.9% since June 2026, when Curaleaf first expressed interest in a potential transaction.
What is the stated cash position of Aurora cited by Curaleaf?
Curaleaf’s application notes that Aurora has described itself as having an “industry-leading balance sheet,” being debt-free, and holding approximately C$149 million in cash, based on Aurora’s own public disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): September 14, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||
(Address of principal executive offices and zip code) | ||||||||
( 917 ) 717 - 5875 | ||||||||
(Registrant's telephone number, including area code) | ||||||||
(Former name or former address, if changed since last report) | ||||||||
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: None.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On September 14, 2026, Curaleaf Holdings, Inc. ("Curaleaf") issued a press release announcing its submission of an application to the Alberta Securities Commission to halt Aurora's share issuance program during Curaleaf's pending offer. A copy of the press release is attached as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number | Description | |||||||
99.1 | Press release dated September 14, 2026 | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CURALEAF HOLDINGS, INC. | |||||||||||
(Registrant) | |||||||||||
Date: | September 14, 2026 | By: | /s/ Peter Clateman | ||||||||
Name: | Peter Clateman | ||||||||||
Title: | Chief Legal Officer | ||||||||||
Curaleaf Holdings, Inc. Investor Relations Curaleaf Submits Application to Alberta Securities Commission to Halt Aurora's ATM Program During Pending Offer Argues Aurora's share issuances are an improper and abusive defensive tactic that dilutes shareholders and interferes with consideration of Curaleaf's premium offer Aurora's ATM issuances have diluted Aurora shareholders by ~11% since implementation of the ATM program and by approximately ~5% since June 2026, and increased the cost of Curaleaf's offer by more than US$11 million STAMFORD, Conn., Sept. 14, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. ("Curaleaf" or the "Company") today announced that it has filed an application (the "Application") with the Alberta Securities Commission ("ASC") to remedy abuse by Aurora of its at-the-market share issuance program (the "ATM Program") by ceasing the issuance of Aurora's shares (the "Shares") under the program while Curaleaf's offer to acquire all of the issued and outstanding Shares (the "Curaleaf Offer" or the "Offer") remains outstanding, and providing other remedies. Curaleaf has requested an expedited hearing before the ASC. "Every Share Aurora sells below the Offer price raises the same question: if management believes US$4.00 undervalues the company and the company has ample cash, why continue diluting its shareholders? These issuances erode shareholder ownership value, increase the cost of the Offer, and make it harder for shareholders to decide their own future. They seem solely designed to protect management's position, at the expense of investors," said Boris Jordan, Chairman and Chief Executive Officer of Curaleaf. "Today, we are taking action to protect Aurora shareholders from ongoing dilution by asking the Alberta Securities Commission to stop Aurora from continuing this abusive practice. Aurora shareholders deserve the freedom to decide whether to accept the Offer without Aurora management creating obstacles that limit their choice and value," concluded Mr. Jordan. The Application sets forth why Aurora's use of the ATM Program is abusive and seeks appropriate remedies: 1. The Use of the ATM Program by Aurora is an Improper and Abusive Defensive Tactic According to Curaleaf's Application, the issuance of Shares under the ATM Program is causing serious and ongoing harm to Curaleaf, Aurora shareholders, and the integrity of Alberta's capital markets. Curaleaf believes Aurora's use of the ATM Program: Increases the total cost of Curaleaf's Offer; Makes it more difficult to reach Offer acceptance thresholds; Further dilutes existing Aurora shareholders; and Risks depriving Aurora shareholders of the opportunity to consider and tender to Curaleaf's Offer. The Application notes that Aurora established the ATM Program in February 2026 and stated that proceeds would be used for "strategic and accretive purposes only." The Application further notes that Aurora has recently described itself as having an "industry-leading balance sheet," being "debt-free," and having approximately C$149 million in cash. Curaleaf believes Aurora's use of the ATM Program while shareholders are considering a premium offer is inconsistent with those stated positions. The Application further alleges that Aurora has been aware of Curaleaf's interest in pursuing a potential transaction since June 2026, yet continued issuing Shares through the ATM Program, including after Curaleaf publicly announced its intention to commence the Offer. 2. The ATM Program Should Be Cease Traded Pending the Offer Curaleaf's Application requests, among other things, that the ASC: Immediately halt further issuances under the ATM Program while the Offer remains outstanding; and Protect Aurora shareholders' ability to fairly consider and respond to Curaleaf's Offer. According to the Application: Aurora has issued approximately 2.81 million Shares at an average price of US$3.04 per Share since Curaleaf first expressed interest to Aurora in pursuing a transaction; Those Share issuances have increased the aggregate value required to complete Curaleaf's Offer by more than US$11 million; Aurora has diluted shareholders by approximately 4.9% over the same period; and, The ATM Program has diluted shareholders by approximately 10.8% since implementation in February 2026.
Curaleaf remains focused on providing Aurora shareholders with a compelling opportunity to realize significant value while participating in the future upside of the world's leading cannabis company. Aurora shareholders are encouraged to read the Offer documents carefully and in their entirety. They are also available on Curaleaf's website and on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov), and Aurora shareholders are encouraged to visit https://grow.curaleaf.com/ for additional information regarding the Offer, including the strategic rationale for the Offer, expected benefits of the combination of the two companies, FAQs, and other relevant materials. IMPORTANT INFORMATION This document does not constitute an offer to buy or the solicitation of an offer to sell any securities. The Offer by Curaleaf to purchase all outstanding Shares is made solely by the Offer to Purchase and Circular dated August 18, 2026, as may be amended or supplemented from time to time. SECURITY HOLDERS ARE URGED TO READ THE OFFER TO PURCHASE AND CIRCULAR, THE REGISTRATION STATEMENT ON FORM F-80, THE TENDER OFFER STATEMENT ON SCHEDULE 14D-1F, AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Free copies are available at www.sec.gov or by contacting the Information Agent, Carson Proxy Advisors, at 1-800-530-5189 (toll- free), 416-751-2066 (local/text), or info@carsonproxy.com. NOTICE TO U.S. SHAREHOLDERS The enforcement by investors of civil liabilities under the federal securities laws may be affected adversely by the fact that the subject company is located in a foreign country, and that some or all of its officers and directors are residents of a foreign country. Investors should be aware that Curaleaf or its affiliates, directly or indirectly, may bid for or make purchases of the Shares or of Aurora's related securities, or of Curaleaf's securities to be distributed or of Curaleaf's related securities, during the period of the Offer, as permitted by applicable Canadian laws. Curaleaf has filed with the SEC a Registration Statement on Form F-80 under the U.S. Securities Act of 1933 and a Tender Offer Statement on Schedule 14D-1F under the U.S. Securities Exchange Act of 1934. The Offer is being conducted in accordance with Section 14(e) of the Exchange Act and Regulation 14E. THE OFFER AND THE CURALEAF SHARES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY U.S. STATE SECURITIES COMMISSION, NOR HAS ANY SUCH AUTHORITY PASSED UPON THE ACCURACY OR ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. The Curaleaf shares have not been registered or otherwise qualified for offer and sale in certain U.S. states where shareholders may reside. No offer is made in those states except to qualifying Exempt Institutional Investors as described in the Offer to Purchase and Circular. FORWARD-LOOKING INFORMATION This document contains "forward-looking information" within the meaning of applicable Canadian securities laws and "forward- looking statements" within the meaning of applicable U.S. securities laws. Such statements relate to, among other things, the expected benefits and anticipated synergies from a combination of Curaleaf and Aurora. Forward-looking statements can often be identified by words such as "believes," "expects," "anticipates," "may," "will," or similar expressions. Actual results may differ materially due to risks including: changes in general economic conditions; failure to satisfy conditions to the Offer; failure to realize anticipated synergies; fluctuations in foreign exchange and interest rates; regulatory changes; and other risks described under "Risk Factors" in the Offer to Purchase and Circular. The PSLRA safe harbor for forward-looking statements does not apply to statements made in connection with a tender offer. Security holders should not place undue reliance on forward-looking information. Curaleaf disclaims any obligation to update forward-looking information except as required by law. AURORA INFORMATION Certain information concerning Aurora herein is based solely on Aurora's publicly available filings and other public sources. Aurora has not reviewed this document. Neither Curaleaf nor its officers or directors assumes responsibility for the accuracy or completeness of such information. ADDITIONAL INFORMATION The disposition of Shares and the acquisition of Curaleaf may have U.S. and Canadian tax consequences; shareholders should consult their own tax advisors. Curaleaf's disclosure documents are available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.
About Curaleaf Curaleaf (TSX: CURA) (OTCQX: CURLF) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf's subordinate voting shares are listed on the Toronto Stock Exchange under the symbol "CURA" and trade on the OTCQX market under the symbol "CURLF". For more information, please visit https://ir.curaleaf.com. Contacts Media Contact Kekst CNC Kekst-Curaleaf@kekstcnc.com Investor Contact Curaleaf Holdings, Inc. IR@curaleaf.com Shareholder Contact Carson Proxy Advisors North American Toll Free Phone: 1-800-530-5189 Local (Collect outside North America): 416-751-2066 Email: info@carsonproxy.com SOURCE Curaleaf Holdings, Inc. https://ir.curaleaf.com/2026-09-14-Curaleaf-Submits-Application-to-Alberta-Securities-Commission-to-Halt-Auroras-ATM- Program-During-Pending-Offer